Delivery Order SPE2DB24D3013-SPE2DB25FFNWE
- Not listed
- The Defense Logistics Agency awarded a $2,395.34 delivery order to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Generation 5 insulin infusion pods. The contract, issued on July 25, 2025, with an ultimate completion date of July 28, 2025, represents a firm fixed price procurement with no set-aside designation. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance for this medical device delivery, which supports the federal government's...
- The Defense Logistics Agency (DLA) awarded a $7,826.55 firm fixed-price delivery order to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Generation 5 pods. The contract, issued on July 21, 2025, with an ultimate completion date of July 22, 2025, represents a non-competitive procurement of specialized diabetic medical devices. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and fulfills the delivery order through its corporate office division....
- The Defense Logistics Agency awarded a $1,372.91 firm fixed price delivery order to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 generation 5 pods on July 22, 2025, with an ultimate completion date of July 23, 2025. This competitively awarded, non-set-aside contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract issued under the company's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a $2,174.98 firm fixed price delivery order to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Generation 5 pods, with performance in Conshohocken, Pennsylvania and completion by July 21, 2025. This non-set-aside competitive award was issued on July 18, 2025, and represents a child delivery order under AmerisourceBergen's larger contract vehicle with DLA Troop Support Medical. The delivery order addresses federal diabetes management and continuous glucose...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,549.48 to AmerisourceBergen Drug Corp for Omnipod 5 Dexcom G7 Generation 5 insulin delivery systems. Issued on July 23, 2025, with a completion date of July 24, 2025, this firm fixed-price delivery order represents a competitive award with no set-aside designation. The award is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $7,950.79 to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 pods (Generation 5), 5-count units, with performance in Conshohocken, Pennsylvania and an ultimate completion date of July 29, 2025. This is a firm fixed-price delivery order issued under a non-set-aside competitive process, representing a child contract under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. This delivery order falls under...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a $25,148.64 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for OmniPod 5 Dexcom G7 Generation 5 insulin infusion pods, with an ultimate completion date of July 24, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor and healthcare solutions provider for...
- The Defense Logistics Agency awarded a delivery order valued at $14,277.78 to AmerisourceBergen Drug Corp for OMNIPOD 5 DEXG7G6 Pods (Generation 5) 5-unit supplies. This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 29, 2025, with performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating it was awarded through open competition based on merit and...
- This delivery order, valued at $3,666.96, was awarded on July 28, 2025, to AmerisourceBergen Drug Corp for the supply of Omnipod 5 Dexcom G7 Generation 5 insulin delivery pods. The contract is a firm fixed price delivery order issued by the Defense Logistics Agency (DLA), a component of the U.S. Department of Defense responsible for supplying medical and pharmaceutical products to military healthcare systems. The place of performance is located in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order valued at $1,833.48 to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Generation 5 insulin delivery pods. The award, issued on July 28, 2025, with an ultimate completion date of July 29, 2025, utilizes firm fixed price pricing and represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical supply...
- SPE2DB24D3013Indefinite Delivery Contract
- SPE2DB24D3013-SPE2DB25FFNWEDelivery Order
The Defense Logistics Agency (DLA) awarded a $17,144.30 delivery order to AmerisourceBergen Drug Corp for OmniPod 5 Dexcom G7 Generation 5 insulin delivery pods. This competitively awarded, firm fixed-price contract is scheduled for completion by July 31, 2025, with performance taking place at the contractor's Conshohocken, Pennsylvania facility. The delivery order carries no set-aside designation and represents a continuation of the company's extensive medical supply support to federal healthcare systems. This delivery order is a child contract issued under AmerisourceBergen Drug Corp's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply pharmaceutical products and medical devices to military and veteran healthcare systems worldwide. AmerisourceBergen's demonstrated capability to meet federal procurement requirements through open competition, combined with its established role as a major pharmaceutical distributor for the Defense Health Agency and other federal healthcare customers, positions it as a critical vendor in the government's medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $17.1k | 7/30/25 |